Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen - LARVOL DELTA

A single-arm, open-label, Phase 4 effectiveness and safety study of tezepelumab in adults and adolescent participants with severe asthma in the United States (clinicaltrialsregister.eu) - P4 | N=400 | Sponsor: AstraZeneca AB

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies. (PubMed, Expert Opin Biol Ther) - "We reviewed pivotal phase 3 and 4 trials (including SINUS-52, SYNAPSE, OSTRO, WAYPOINT, and the head-to-head EVEREST trial) evaluating dupilumab, mepolizumab, benralizumab, omalizumab, and tezepelumab. Emerging data from the WAYPOINT trial suggests tezepelumab (anti-TSLP) as a potent option for broad epithelial blockade. We advocate moving beyond isolated disease control toward a stratified 'United Airway' remission target guided by fractional exhaled nitric oxide, blood eosinophils, and immunoglobulin E levels."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5

Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea (clinicaltrials.gov) - P=N/A | N=210 | Not yet recruiting | Sponsor: AstraZeneca | N=150 ➔ 210

Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Delivering Severe Asthma Care in the Real World: Insights into Anti-TSLP (Tezepelumab) Use from a Tertiary Allergy and Respiratory Centre (EAACI 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Allergy • Immunology

Inhibitory Effects of Tezepelumab on Proinflammatory Mediators in Nasal Lining Fluid from Patients with CRSwNP in the Phase 3 WAYPOINT Study (EAACI 2026) - No abstract available

Clinical • P3 data • Allergy • Immunology

Real-World Outcomes Of Tezepelumab In Severe Asthma After 12 Months Of Treatment (EAACI 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology

Clinical outcomes and biomarker levels after cessation of tezepelumab treatment in adults with severe CRSwNP from WAYPOINT (EAACI 2026) - No abstract available

Biomarker • Clinical • Clinical data • Immunology • Inflammation

Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study (EAACI 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology

Impact of tezepelumab on bronchial hyperreactivity in adolescents with severe allergic asthma: preliminary data from a prospective multicenter observational study (EAACI 2026) - No abstract available

Clinical • Observational data • Immunology

Tezepelumab Reduces Urine Levels of Eicosanoid Metabolites Indicative of Mast Cell Activation in Patients with Moderate to Severe, Uncontrolled Asthma: Results from the Phase 2 CASCADE Trial (EAACI 2026) - No abstract available

Clinical • P2 data • Immunology

Early and Clinically Meaningful Improvements in Nasal Polyp Symptoms Following Tezepelumab Treatment in Adults with Chronic Rhinosinusitis with Nasal Polyps: Interim Results from the Phase 3b ESSENCE Study (EAACI 2026) - No abstract available

Clinical • P3 data • P3 data: top line • Allergy • Immunology

Efficacy of Tezepelumab in Chinese Patients with Severe Uncontrolled Asthma and Comorbidities: A Post-Hoc Analysis of the DIRECTION Study (EAACI 2026) - No abstract available

Clinical • Retrospective data • Immunology

Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study (EAACI 2026) - No abstract available

HEOR • Real-world • Real-world evidence • Retrospective data • Immunology

Transformative response to Tezepelumab in severe asthma with severe airflow limitation: a case study (EAACI 2026) - No abstract available

Case study • Clinical • Immunology

Use of Tezepelumab in four Patients with Allergic Bronchopulmonary Aspergillosis and severe uncontrolled Asthma: A Case Series (EAACI 2026) - No abstract available

Clinical • Immunology

Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study (EAACI 2026) - No abstract available

Clinical • Immunology

Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study (EAACI 2026) - No abstract available

Clinical • Immunology

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma. (PubMed, Cureus) - "After switching from mepolizumab to tezepelumab, her symptoms rapidly resolved; forced expiratory volume in one second (FEV₁) increased from 0.64 L (45.7% predicted) to 1.45 L (103% predicted) within two months, and the concave flow-volume loop became almost normal. This case suggests that chronic airflow limitation in severe asthma is not always irreversible and that switching to tezepelumab may induce dramatic functional recovery even after anti-IL-5 therapy."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL5

Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma. (PubMed, J Inflamm Res) - "Evidence on biologic withdrawal is more heterogeneous: discontinuation of mepolizumab, tezepelumab or omalizumab frequently leads to loss of control, although a subset maintains remission off-treatment. This proposed pathway is presented as a pragmatic synthesis of the available evidence and should be interpreted as expert opinion rather than formal guideline recommendations. Robust, standardized definitions and validated predictors are still needed to safely expand off-treatment remission to a larger proportion of patients."

Biomarker • Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL5 • TSLP

DIRECTION Study (clinicaltrialsregister.eu) - P4 | N=220 | Not yet recruiting | Sponsor: Medical University Of Vienna

New P4 trial • Real-world evidence • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Evidence-Based Information on Newer Drugs for Chronic Spontaneous Urticaria (AAD 2026) - " Bruton Tyrosine Kinase inhibitors, remibrutinib and fenebrutinib, are fast-acting, oral medications with a favorable safety and efficacy in CSU and greater potency in type IIb autoimmune urticaria...Quilizumab, canakinumab, Tezepelumab, and benralizumab are not beneficial in CSU. BTK inhibitors are efficacious in CSU and may be superior to omalizumab for type IIb autoimmune urticaria, where disease control is often delayed and limited with anti-IgE agents. Ligelizumab and dupilumab are safe and effective alternatives to omalizumab for anti-histamine-resistant CSU."

Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria • IL4 • IL4R

Refractory Status Asthmaticus in a Patient on VV ECMO Augmented by Rescue Therapy With Omalizumab (SCCM 2026) - "For patients who fail standard ICU management, VV ECMO or inhaled anesthetics such as sevoflurane may be offered. There is growing numbers of case reports of "off label" or compassionate use of biologic agents such as anti-IGE omalizumab, anti-IL-5Ra benralizumab, and anti-TSLP tezepelumab...The patient was discharged home on room air five days later to follow up with pulmonology for his asthma. Our patient showed improved ventilation at 48 hours and was able to be extubated and decannulated at day 9, this is consistent with the limited established literature and tracks with omalizumab's onset of action of 7-8 days. Our case adds to the growing number of case reports describing the use of biologic agents in refractory status asthmaticus and is one of a handful of cases in a patient on VV ECMO."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Eosinophilia • Immunology • Respiratory Diseases

ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) - P=N/A | N=513 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

HEOR • Real-world evidence • Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Biologics in Severe Asthma: From Precision Phenotyping to Clinical Remission. (PubMed, J Asthma) - "We included pivotal randomized controlled trials, real-world evidence studies, systematic reviews, and meta-analyses focusing on approved biologics (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) and emerging agents for severe asthma. Biologics have made clinical remission an attainable goal for many patients. Future research must focus on therapies for non-type 2 asthma, refining dynamic biomarkers, and establishing long-term disease-modifying effects."

Journal • Review • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Dual clinical remission in patients treated with biologics for severe asthma and eosinophilic chronic rhinosinusitis. (PubMed, Allergol Int) - "Dual CR with biologics treatment may be achieved in elderly patients and in those with N-ERD among patients with both SA and ECRS."

Journal • Asthma • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis